Intermediate Efavirenz Powder Raw Material Efavirenz Powder Efavirenz

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Model NO.: D-sung Efavirenz
• Appearance: White Powder
• Color: White
• Store: Cool and Dry
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anthelmintics
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 154598-52-4
• Mf: C14h9clf3no2
• Boiling Point: 340.6 C at 760 Mmhg
• Melting Point: 139-141
• Model No.: D-Sung Efavirenz
• Product Name: Efavirenz
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• HS Code: 2942000000
• Production Capacity: 500kg/Month

Product Description

 

Product Description

Intermediate Efavirenz powder Raw Material Efavirenz powder Efavirenz

Product Description

Product Details

Product Name	Efavirenz
Appearance	White Powder
CAS No.	154598-52-4
MF	C14H9ClF3NO2

Efavirenz D5 (Sustiva)84 is also mandated for use with at leasttwo other antiretroviral agents. The compound is morethan 99% protein bound, and CSF concentrations exceedthe free fraction in the serum. Metabolism occurs in theliver. The half-life of a single dose of Efavirenz D5 is 52 to 76hours, and 40 to 55 after multiple doses (the drug inducesits own metabolism). Peak concentration is achieved in 3to 8 hours. Elimination is 14% to 34% in urine (as metabolites)and 16% to 41% in feces (primarily as Efavirenz D5).The oral dosage form is supplied as a capsule.

Application&Function

Efavirenz is one of the most commonly prescribed antiretroviral medications in the world. Several large randomized, controlled trials[RCTs] have demonstrated the superior ability of efavirenz to suppress the HIV virus when used as part of a 3-drug cocktail. The introduction of Atripla in 2006 combined efavirenz and two other agents into a single pill, once-daily formulation. This formulation was more convenient and better tolerated than alternatives, and thus resulted in improved adherence to antiretroviral medications. However, neuropsychiatric side effects associated with efavirenz have been reported to occur in 40-50% of patients and represent one of the limiting factors of this regimen.

Specification